Israeli researchers at a blood cancer conference in the US reported a lymphoma treatment that can achieve 100% survival rates ...

A study published in the Journal of Clinical Oncology confirms that one of the first Food and Drug Administration-approved ...

In this phase 2 study, researchers sought to determine whether cytoreductive treatment with rituximab followed by epcoritamab would deepen responses and lower risk of cytokine release syndrome.

Lyell management will host an investor webcast with presenting author and ronde-cel investigator Sarah M. Larson, MD, ...

In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction ...

R 2 is the only second-line alternative to chemoimmunotherapy-based treatment for patients with relapsed/refractory ...

Jaypirca (pirtobrutinib) improved progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) when compared with bendamustine ...